Annual Report & ACCOUNTS for the year ended 30 June 2014

HYR 2014

STRENGTHENING OUR POSITION WITHIN THE GLOBAL ANIMAL HEALTH MARKET

View Overview

Our Business and Strategy

View Our Group at a Glance

Our Performance

View Our Performance

Our Governance

View Our Governance

Our Financials

View Our Financials

Highlights

Total Revenue

£193.6m

2013: £189.2m

CER*: Up 1.6%

£: Up 2.3%

View Highlights

EU Pharma Revenue

£172.4m

2013: £168.7m

CER*: Up 1.0%

£: Up 2.2%

View Highlights

US Pharma Revenue

£21.2m

2013: £20.5m

CER*: Up 6.8%

£: Up 3.4%

View Highlights

Underlying Operating Profit

£42.2m

2013: £39.1m

CER*: Up 7.2%

£: Up 7.9%

View Highlights

Underlying Diluted Earnings per Share

36.32p

2013: 29.07p

CER*: Up 23.9%

£: Up 24.9%

View Highlights

Dividend per Share

15.40p

2013: 14.00p

CER*: Up 10.0%

£: Up 10.0%

View Highlights